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Abstract
Introduction. Myocardial perfusion scintigraphy (MPS) with dipyridamole is an accepted method for assessment of is-
chaemic heart disease, in case of contraindication to exercise testing. However, very often we observe clinical symptoms 
and changes in ECG while monitoring patients during the study with pharmacologic stress with dipyridamole. The aim 
of this study was to investigate the safety of patients diagnosed with MPS with dipyridamole.
Material and methods. Twenty-five patients with stable coronary artery disease participated in a 2-day protocol (0.56 mg/
kg dipyridamole i.v. and then rest) using Tc-MIBI imaging. Continuous clinical monitoring and 12-lead serial ECG has been 
used since the beginning of the MPS up to 20 minutes after the examination. High-sensitive cardiac troponin I (hscTnI) 
concentration was measured before, four hours and the next day after stress test. Primary endpoint included hscTnI 
concentration above 99th percentile of the upper reference limit in second or third measurement or new persistent ST-T 
segment changes. Secondary endpoints were: new persistent or transient ECG changes (ST-T segment elevation or 
depression or negative T waves, prolongation of QRS complex, PR interval or QTc), or any drug-related adverse event.
Results. The concentrations of hscTnI were below 99th percentile of the upper limit among all the patients. Primary and 
secondary endpoint were observed in 6 (24%) and 23 (92%) patients, respectively. Transient ST-T segment elevation 
occurred in 4 (16%) patients, transient ST-T segment depression or negative T wave — in 7 (25%) patients, QRS complex 
prolongation — in 11 (44%) patients, PR interval prolongation — in 18 (75%) patients, QTc prolongation — in 22 (88%) 
patients, any clinical adverse event related to dipyridamole — in 16 (64%) patients. Following endpoints were correlated 
with positive MPS results: ST-T segment changes, RP interval prolongation, and with a history of chest pain: ST-T seg-
ment changes, QRS complex and QTc prolongation.
Conclusions. MPS with dipyridamole stress is relatively safe, as hscTnI concentration remains within normal in prolon-
ged observation after the examination. While there is a significant risk of minor clinical and electrocardiographic adverse 
events it is not related with a myocardial necrosis.
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Introduction
Myocardial perfusion scintigraphy (MPS) is one of the most 
important and commonly performed non-invasive imaging 
test in diagnosis of ischemic heart disease [1]. European 
Association of Nuclear Medicine and European Society of 
Cardiology guidelines emphasizes high sensitivity (about 
90%) and specificity (about 80%) of MPS in detecting 
haemodynamic obstructive coronary artery disease (CAD) 
[2, 3]. The prognostic power of MPS has been extensively 
evaluated, and several studies have demonstrated that 
myocardial perfusion imaging has an independent rela-
tionship with subsequent major adverse cardiac events 
[4, 5]. Moreover, it adds incremental prognostic value to 
the information obtained from patient clinical variables, 
stress test and angiographic findings [4–6].
There are several different protocols for performing 
a MPS. Usually MPS is a two-step examination: a ‘stress’ 
part and a ‘rest’ part, to allow comparison of blood flow 
during stress and rest [2, 3]. During the stress part of the 
test, the heart is made to work either with exercise testing 
on a treadmill [7], or alternatively with infusion of a drug. 
Pharmacological vasodilatation with e.g. dipyridamole is 
indicated for patients who are unable to exercise or una-
ble to increase their heart rate, patients with left bundle 
branch block or paced ventricular rhythm [2].
In everyday practice, we observe both clinical symp-
toms and electrocardiography (ECG) changes during phar-
macological stress study. With a high sensitivity cardiac 
troponin I (hscTnI) we may reliably evaluate the risk of 
myocardial necrosis related to the study. Thus, the aim of 
this study was to assess the safety of dipyridamole testing 
in patients undergoing MPS.
Material and methods
Study population
We performed a single-center, prospective study of 25 con-
secutive patients with stable CAD (SCAD), who underwent 
MPS. The analysis excluded those patients hscTnI concen-
tration above 99th percentile of the upper reference limit.
The ethical approval before initiation of the study was 
obtained and all patients provided informed consent.
Myocardial perfusion scintigraphy protocol
The MPS studies were performed using a 2-day stress/
rest Tc-99m-MIBI protocol, with injection of 740 MBq 
Tc-99m-MIBI (NCBJ or POLATOM, Poland) at stress and 
rest study. Stress and rest acquisition began about 50–60 
min after the end of the injection of Tc-99m-MIBI. Images 
were obtained according to established clinical protocols, 
using gated hybrid SPECT/computed tomography (CT) 
with a dual-head gamma camera (Symbia T6 Siemens, 
Erlangen, Germany). Patients were imaged in the supine 
position. Low energy high-resolution collimator and a zoom 
factor of 1.0 were used. We obtained 32 projections in 
a 128 × 128 matrix, with an acquisition time of 25 s per 
projection. The energy window width for scatter correction 
was centered at 140 keV and with width of 15%. At the 
end, a low-dose CT attenuation correction (CTCA) was 
performed using imaging settings: 130 ke, 13 mAs/slice 
(slice thickness of 5 mm).
Patients were stressed using pharmacological test with 
dipyridamole. Medications that contain methylxanthines 
or caffeine and food beverage with caffeine have been 
withdrawn 12–24 hours prior to procedure. Dipyridamole 
was infused over a 4-min period at a dose of 0.56 mg/kg 
diluted in normal saline solution. Radiopharmaceutical was 
injected at the 7th–8th minute of the infusion.
Normal MPS was defined as visually homogeneous 
and quantitative analysis presenting no perfusion defect, 
with all parameters obtained from the gated-SPECT within 
normal.
Positive MPS was defined as a perfusion defect re-
version over 10% of left ventricle mass during the rest 
examination.
Clinical assessment and follow-up
Patients were assessed for clinical signs and symptoms of 
angina by a physician. The concentration of hscTnI (ADVIA 
Centaur TnI-Ultra® Assay, Siemens, Germany) was measu-
red two hours before MPS (first assessment), four hours 
after pharmacological stress with dipyridamole (second 
assessment) and the next day after examination (third 
assessment). According to the product characteristics, 99th 
percentile upper normal limit is 40 ng/L (pg/mL).
Continuous clinical monitoring and 12-lead serial ECG 
examination have been used since the beginning of the 
MPS up to 20 min after the examination. ECG was per-
formed every three minutes and analyzed for significant 
ST segment elevation or depression or negative T waves 
in any lead and prolongation of PR interval, QRS complex 
or QTc by a second physician. Every new ST-T segment 
change was classified as transient or persistent due to its 
presence 20 min after the end of MPS.
Study endpoints
Primary endpoint was a composite of hscTnI concentration 
above 99th percentile of upper normal limit in second or 
third assessment or new persistent ST-T changes.
Secondary endpoints were:
 — hscTnI concentration four hours after pharmacological 
stress (in the second assessment) higher than before 
MPS (in the first assessment);
 — new ECG changes (transient ST segment elevation or 
depression or negative T waves, prolongation of QRS 
complex, PR interval or QTc) during an examination;
 — any drug-related adverse event (AE).
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Statistical analysis
Statistical analysis was performed using Statistica v. 12. 
Quantitative variables are expressed as mean ± standard 
deviation and median (first and third quartile value). Ca-
tegorical variables are presented as an exact number and 
percentage of patients. Differences between two groups for 
continuous variables were tested by Mann-Whitney U-test. 
The comparisons of categorical variables were analyzed 
using χ2 independence test. Two-way tables were assessed 
with the χ2 test with double-sided Fisher’s exact test due to 
limited number of patients. A P value < 0.05 was defined 
as statistically significant.
Results
The study group included 25 patients (mean age 68.5 ± 
8.9 years; women, 52%. Primary endpoint was observed 
in 6 (24%) patients due to ECG permanent ST-T segment 
changes. Concentration of hscTnI remained within normal 
range among every patient during the study. We observed 
differences between compared groups, however large-scale 
data could provide greater statistical reliability. Detailed 
characteristics of patients that reached and did not reach 
primary endpoint was presented in Table 1.
Secondary endpoint was observed in 23 (92%) patients 
and the most frequent items were as follows: QTc prolon-
gation in 22 (88%) patients and PR interval prolongation in 
18 (72%) patients. Increased hscTnI concentration (within 
normal range) was observed in about half of patients four 
hours after pharmacological stress. Clinical AE related 
to dipyridamole were rather often — 16 (64%) patients 
experienced at least one AE. The frequency of secondary 
endpoints was presented in Table 2.
Additional analysis was performed to assess correla-
tions between reported AE and clinical factors. More than 
80% of patients with QTc prolongation reported chest pain. 
New transient or persistent ST segment depression or 
negative T waves were present only among patients wit-
hout a history of chest pain (p = 0.01) and correlated with 
positive MPS (p = 0.04). History of chest pain was present 
in 10 per 11 patients with QRS complex prolongation (p = 
0.0001). PR interval prolongation was present in 13 and 
5 patients without and with a positive MPS, respectively 
(p = 0.056).
Discussion
Dipyridamole prevents the intracellular reuptake and 
deamination of adenosine [8]. It is an indirect coronary 
artery dilatator increasing myocardial blood flow during 
stress on the order of three to five times [7–10]. Stimu-
lating adenosine 2A receptors (A2A) dipyridamole induce 
myocardial hyperaemia [8]. But diseased coronary artery 
has a reduced perfusion reserve. Thus, the drug provokes 
perfusion heterogeneity or even ischemia of myocardium 
supplied by diseased coronary artery due to coronary steal 
[2, 3]. However, besides A2A receptors adenosine stimu-
lates A1, A2B and A3 receptors too, resulting in various 
clinical adverse effects [11, 12].
Clinical and ECG monitoring extended up to 20 minutes 
after the MPS, is a result of clinical observations of pa-
tients who underwent the examination at our center. In the 
Table 1. Characteristic of study group and subgroups per met primary endpoint*
 All patients 
(N = 25)
Primary endpoint positive 
(N = 6)
Primary endpoint negative 
(N = 19)
p
Females 13 (52) 2 (33.3) 11 (57.9) 0.3782
Age (years) 68.5 ± 8.9 69.83 + 7.57 68.05 + 9.46 0.7739
Diabetes 5 (20) 2 (33.3) 3 (15.8) 0.5622
SCAD symptomes:
• chest pain 19 (76) 5 (83.3) 14 (73.7) 1.0
• angina pectoris 14 (56) 4 (66.7) 10 (52) 0.6608
MPS:
• within normal 5 (20) 1 (16.7) 4 (21.1) 1.0
• possitive 8 (32) 3 (50) 5 (26.3) 0.3441
hscTnI concentration (ng/L):
• 1st assessment 5.28 ± 6.88 6.67 ± 8.38 4.84 ± 6.53 0.6928
• 2nd assessment 6.04 ± 8.89 8.5 ± 7.06 5.26 ± 9.43 0.3237
• 3rd assessment 5.68 ± 8.07 2.33 ± 3.2 6.74 ± 8.89 0.3397
*Continuous variables were presented as median (interquartile range) and categorical variables are presented as absolute numbers (percentages). P values are given for differences between the patients 
who met and did not meet primary endpoint; N — number of patients; SCAD — stable coronary disease; MPS — myocardial perfusion scintigraphy; hscTnI — high-sensitivity cardiac troponin I
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study, we assessed the biochemical markers of ischemia 
(with high sensitivity), ECG changes and clinical adverse 
events related to the drug. Dynamic changes in collected 
data allows to conclude about patients’ safety.
The study showed no increased hscTnI levels above 
99th percentile of upper reference limit. We observed 
increased hscTnI concentration four hours after MPS 
from baseline in 12 (48%) patients, but it was below 99th 
percentile of upper reference limit. Clinical symptoms and 
ECG changes (even permanent) are insufficient to diagnose 
myocardial infarction per current definition [13]. However, 
within patients who met primary endpoint, the hscTnI 
levels were higher (6.7 ± 8.4 mg/L vs 4.8 ± 6.5 ng/L, p = 
0.69). Lack of statistical significance is comprehensible 
due to low number of patients. However, it is well known, 
that among patients with SCAD hscTnI concentration (even 
within normal) is an efficient tool to stratify the risk of poor 
prognosis in short- and long-term observation [14–16]. To 
the best of our knowledge this is one of the first announ-
cements of possible negative influence of dipyridamole 
pharmacologic stress test on hscTnI concentration and 
multiple ECG changes in stable patients.
Ischaemic changes in ECG were observed in the study 
group after pharmacological stress. Especially alarming 
were persistent changes of the ST-T segment. New persi-
stent elevation or depression of ST segment were observed 
in 25% of patients and correlated with the positive MPS 
and history of chest pain. It is a crucial observation as 
the clinical meaning of new changes in ECG during MPS 
study was never assessed. Nevertheless, we may reject the 
hypothesis of myocardial necrosis as the hscTnI concen-
tration remains within normal in prolonged observation.
Recent analyzes regarding the safety of dipyridamole 
do not differentiate between persistent and transient ST-T 
segment changes. In the paper published by Doumas 
A et al [17], new ST-T changes were observed in 5 out 
of 41 (12%) patients after dipyridamole administration. 
Out of 125 patients evaluated in the Zaman et al. study, 
78 (68.4%) had some form of minor adverse reactions e.g. 
chest pain was experienced by 39 cases (31%) and ST-T 
changes occurred in 36 (29%) patients who underwent 
dipyridamole perfusion imaging [18]. Compared to mentio-
ned studies, this study is distinguished by the stratification 
method of ST-T segment changes considering their dyna-
mics during and after the pharmacologic stress test. There 
are also no publications validating ST-T changes during 
MPS as a risk factor for significant cardiovascular events.
Among other changes in the ECG, QTc prolongation 
and PR prolongation were observed most frequently. In 
Guideri et al. [19] study, twenty-five patients admitted for 
evaluation of chest pain of suspected myocardial origin 
after discontinuation of antianginal treatment underwent 
an echocardiographic stress test. Of these patients, 10 un-
derwent an echocardiographic adenosine stress test and 
15 underwent an echocardiographic dipyridamole stress 
test. After dipyridamole and adenosine administration, 
a significant prolongation of the QTc interval was observed 
only in those patients who had positive test results [19]. 
Interestingly, in our study over 80% of patients with QTc pro-
longation reported chest pain and about 60% of patients 
had typical angina before the examination. Although, we 
have shown no correlation between QTc prolongation and 
the MPS, our results confirms Guideri’s suggestions that 
QTc interval prolongation during pharmacological stress 
tests might be considered as a marker of myocardial 
ischemia.
The relatively frequent occurrence of clinical AE (64% 
of patients) is noteworthy. The authors reported all AEs re-
gardless of their severity. In the literature, we found reports 
of the occurrence of AE after intravenous administration 
of dipyridamole in 40 to nearly 70% of patients [19, 20].
The main limitation of our study is the limited number 
of patients. It is a single-center pilot study designed to 
assess the safety of the dipyridamole administration du-
ring the MPS with a modern study protocol. Per authors’ 
knowledge and experience this is an observation worth to 
Table 2. Prevalence of adverse events in studied group
Primary endpoint Value
Positive hscTnI assessment* 0 (0)
New persistent ST segment elevation or 
depression
6 (25)
Secondary endpoint
Increased hscTnI concentration** 12 (48)
New transient or persistent ST segment 
elevation
4 (16)
New transient or persistent ST segment 
depression or negative T waves
7 (28)
QRS complex prolongation 11 (44)
PR interval prolongation 18 (72)
QTc prolongation 22 (88)
Any dipyridamole-related adverse event: 16 (64)
• headache 15 (60)
• dizziness 1 (4)
• chest pain 4 (16)
• angina pectoris 3 (12)
• dyspnoea 5 (20)
• heat 1 (4)
• excessive sweatting 6 (24)
• fatigue 1 (4)
• palpitations 1 (4)
*hscTnI concentration above 99th percentile of the upper normal limit in second or third 
assessment; **hscTnI concentration in the second assessment higher than in the first one; 
categorical variables are presented as absolute numbers (percentages); hscTnI — high-sensitivity 
cardiac troponin I
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highlight to make further studies, including a larger study 
population, that confirm our findings.
Conclusions
MPS with dipyridamole stress is related to significant risk 
of clinical and electrocardiographic adverse events. There 
is a considerable number of ECG changes with undetermi-
ned clinical implication (especially QRS complex and QTc 
prolongations) related to dipyridamole infusion.
Conflict(s) of interest
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Streszczenie
Wstęp. Scyntygrafia perfuzyjna mięśnia sercowego (MPS) z obciążeniem dipirydamolem jest szeroko akceptowaną 
metodą oceny niedokrwienia mięśnia sercowego, szczególnie u pacjentów z przeciwwskazaniami do elektrokardiogra-
ficznego testu wysiłkowego. Jednak podczas obciążenia dipirydomolem często obserwuje się objawy kliniczne i zmiany 
w badaniu elektrokardiograficznym (EKG). Celem badania jest określenie bezpieczeństwa badań MPS z obciążeniem 
dipirydamolem.
Materiał i metody. Do badania włączono kolejnych 25 pacjentów, u których wykonywano badanie MPS w celu diagno-
styki niedokrwienia mięśnia sercowego w protokole dwudniowym (po obciążeniu dipirydamolem w dawce 0,56 mg/kg 
mc. i.v. i w spoczynku). Badania wykonywano z wykorzystaniem Tc-MIBI. W trakcie badania pacjenci byli monitorowani 
za pomocą 12-odprowadzeniowaego EKG. U wszystkich pacjentów oznaczono stężenie troponiny I metodą wysokoczułą 
(hscTnI) przed badaniem, 4 godziny po obciążeniu dipirydamolem i następnego dnia. Pierwszorzędowym punktem koń-
cowym było stężenie hscTnI ponad 99. percentyla górnej granicy wartości referencyjnej w 2. lub 3. oznaczeniu albo nowe 
i utrzymujące się zmiany odcinka ST-T. Drugorzędowym punktem końcowym były nowe przemijające lub utrzymujące się 
zmiany w zapisie EKG (uniesienie lub obniżenie odcinka ST-T, wydłużenie czasu trwania zespołu QRS, odstępu PR lub 
skorygowanego czasu QT [QTc]) lub jakiekolwiek zdarzenie niepożądane związane z dipirydamolem.
Wyniki. Stężenia troponiny w kolejnych pomiarach mieściły się w wartościach referencyjnych u wszystkich pacjentów. 
Pierwszorzędowy i drugorzędowy punkt końcowy obserwowano u odpowiednio 6 (24%) i 23 (92%) badanych. Przemi-
jające uniesienie odcinka ST-T wystąpiło u 4 (16%) badanych, przemijające obniżenie odcinka ST lub ujemne załamki 
T u 7 (25%) badanych, wydłużenie zespołu QRS u 11 (44%) badanych, odstępu PR u 18 (75%) badanych, QTc u 22 
(88%) badanych, a jakiekolwiek zdarzenie niepożądane związane z lekiem u 16 (64%) badanych. Obecność punktów 
końcowych korelowała z dodatnim wynikiem badania MPS (zmiany odcinka ST-T, wydłużenie odstępu PR) i wywiadem 
dolegliwości dławicowych (zmiany odcinka ST-T, wydłużenie zespołu QRS i QTc).
Wnioski. Stężenie hscTnI w granicy normy w przedłużonej obserwacji pacjentów po badaniu MPS z obciążeniem dipiry-
damolem wskazuje na to, że jest to względnie bezpieczna procedura diagnostyczna. W trakcie badania obserwuje się 
zmiany elektrokardiograficzne i kliniczne zdarzenia niepożądane niezwiązane z martwicą miokardium.
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